2026-07-16T14:21:21Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/99182025-05-05T15:05:25Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16958col_20.500.12105_16967col_20.500.12105_16982col_20.500.12105_16985col_20.500.12105_16988

00925njm 22002777a 4500 dc Blasco, Lucia author Ambroa, Antón author Trastoy, Rocío author Bleriot, Ines author Moscoso, Miriam author Fernández-García, Laura author Pérez-Nadales, Elena author Fernández-Cuenca, Felipe author Torre-Cisneros, Julian author Oteo-Iglesias, Jesus author Oliver, Antonio author Cantón, Rafael author Kidd, Tim author Navarro, Ferran author Miró, Elisenda author Pascual, Álvaro author Bou, Germán author Martínez-Martínez, Luis author Tomas, Maria author 2020-04-28 The emergence of multidrug resistant (MDR) pathogenic bacteria is jeopardizing the value of antimicrobials, which had previously changed the course of medical science. In this study, we identified endolysins ElyA1 and ElyA2 (GH108-PG3 family), present in the genome of bacteriophages Ab1051Φ and Ab1052Φ, respectively. The muralytic activity of these endolysins against MDR clinical isolates (Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae) was tested using the turbidity reduction assay. Minimal inhibitory concentrations (MICs) of endolysin, colistin and a combination of endolysin and colistin were determined, and the antimicrobial activity of each treatment was confirmed by time kill curves. Endolysin ElyA1 displayed activity against all 25 strains of A. baumannii and P. aeruginosa tested and against 13 out of 17 strains of K. pneumoniae. Endolysin ElyA2 did not display any such activity. The combined antimicrobial activity of colistin and ElyA1 yielded a reduction in the colistin MIC for all strains studied, except K. pneumoniae. These results were confirmed in vivo in G. mellonella survival assays and in murine skin and lung infection models. In conclusion, combining colistin (1/4 MIC) with the new endolysin ElyA1 (350 µg) enhanced the bactericidal activity of colistin in both in vitro and in vivo studies. This will potentially enable reduction of the dose of colistin used in clinical practice. Blasco L, Ambroa A, Trastoy R, Bleriot I, Moscoso M, Fernandez-Garcia L, et al. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. Sci Rep. 2020 Apr 28;10(1):7163. 10.1038/s41598-020-64145-7 2045-2322 2045-2322 Scientific reports http://hdl.handle.net/20.500.13003/10931 32346029 L631657427 2-s2.0-85083992764 http://hdl.handle.net/20.500.12105/9918 560713100014 In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens